

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 1 (Currently Amended): A modified anti-viral peptide comprising: a peptide, ~~comprising an~~ the amino acid sequence of which is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, ~~and~~ SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, and that exhibits anti-viral activity against human immunodeficiency virus (HIV), and a succinimidyl or maleimide containing group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds.

Claim 3 (Previously Presented): The modified peptide of claim 1 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

Claim 4 (Currently Amended): The modified peptide of claim 1 wherein said peptide is DP 178, ~~and comprises~~ the amino acid sequence of which is SEQ ID NO:1.

Claim 6 (Currently Amended): The modified peptide of claim 1 wherein said peptide ~~is~~ has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, ~~and~~ SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claim 19 (Currently Amended): A composition for use in the prevention and/or treatment of acquired immune deficiency syndrome (AIDS) comprising a peptide, ~~wherein the amino acid sequence of which said peptide comprises the amino acid sequence is~~ selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, ~~and~~ SEQ ID NO: 5, SEQ ID

NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, and that exhibits anti-viral activity against human immunodeficiency virus (HIV), modified with a succinimidyl or maleimide containing group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds, in a physiologically acceptable medium.

Claim 20 (Previously Presented): The composition of claim 19 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

Claim 21 (Currently Amended): The composition of claim 20 wherein said peptide is DP 178, ~~comprising~~ the amino acid sequence of which is SEQ ID NO:1.

Claim 31 (Currently Amended): The composition of claim 19 wherein said peptide ~~comprises~~ has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, ~~and~~ SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claim 32 (Previously Presented): A conjugated peptide comprising the modified anti-viral peptide of claim 1 covalently bonded to a blood component.

Claim 33 (Previously Presented): The conjugated peptide of claim 32 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

Claim 34 (Currently Amended): The conjugated peptide of claim 32, wherein said modified anti-viral peptide ~~comprises~~ has the amino acid sequence of SEQ ID NO:1.

Claim 35 (Currently Amended): The conjugated peptide of claim 32, wherein said modified anti-viral peptide ~~comprises~~ has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, ~~and~~ SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claim 36 (Currently Amended): A composition comprising the modified anti-viral peptide of claim 1 in a physiologically acceptable medium.

Claim 37 (Previously Presented): The composition of claim 36 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

Claim 38 (Currently Amended): The composition of claim 36 wherein said modified anti-viral peptide ~~comprises~~ has the amino acid sequence of SEQ ID NO:1.

Claim 39 (Currently Amended): The composition of claim 36 wherein said modified anti-viral peptide ~~comprises~~ has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claim 40 (Previously Presented): A composition comprising the conjugated peptide of claim 31.


Claim 41 (Previously Presented): The composition of claim 40 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

Claim 42 (Currently Amended): The composition of claim 40 wherein said modified anti-viral peptide ~~comprises~~ has the amino acid sequence of SEQ ID NO:1.

Claim 43 (Currently Amended): The composition of claim 40 wherein said modified anti-viral peptide ~~comprises~~ has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, ~~and~~ SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.


Claims 44-51 (Cancelled)

Claim 52 (Previously Presented): The modified anti-viral peptide of claim 1 having the formula:




((SEQ ID NO:1)-Lys-(ε-MPA)).

Claim 53 (Previously Presented): The composition of claim 19 comprising the modified peptide formula:




((SEQ ID NO:1)-Lys-(ϵ -MPA)).

Claim 54 (Previously Presented): The conjugated peptide of claim 32 comprising the modified peptide formula:



((SEQ ID NO:1)-Lys-(ϵ -MPA)).

Claim 55 (Previously Presented): The composition of claim 36 comprising the modified peptide formula:



((SEQ ID NO:1)-Lys-(ϵ -MPA)).

Claim 56 (Previously Presented): The composition of claim 40 wherein the conjugated peptide comprises the modified peptide of formula:



((SEQ ID NO:1)-Lys-(ϵ -MPA)).

Claims 57-58 (Cancelled)